Hormone-Refractory Prostate Cancer Recruiting Phase 1 Trials for Niraparib (DB11793)

Also known as: Hormone-refractory Prostate Cancer / Hormone refractory prostate cancer

IndicationStatusPhase
DBCOND0030169 (Hormone-Refractory Prostate Cancer)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03076203Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)Treatment